Fetal bovine serum

Last updated
Bottle of FBS for cell culture Fetal bovine serum cell culture medium.jpg
Bottle of FBS for cell culture

Fetal bovine serum (FBS) is the most widely used serum-supplement for the in vitro cell culture of eukaryotic cells. It is commonly utilized in biomedical research, pharmaceutical development, and biomanufacturing due to its ability to support a wide variety of cell types. [1] This is due to it having a very low level of antibodies and containing more growth factors, allowing for versatility in many cell culture applications. Fetal bovine serum is derived from the blood drawn from a bovine fetus via a closed system of collection at the slaughterhouse.

Contents

The globular protein bovine serum albumin (BSA) is a major component of fetal bovine serum. It plays a crucial role in maintaining osmotic balance and transporting molecules within the culture medium. Besides BSA, fetal bovine serum is a rich source of growth and attachment factors, lipids, hormones, nutrients and electrolytes necessary to support cell growth in culture. It is typically added to basal cell culture medium, such as DMEM or RPMI, at a 5–10% concentration.

Because it is a biological product, FBS is not a fully defined media component, and as such varies in composition between batches. [2] As a result of this and in an attempt to minimize the possibility of transfer of adventitious agents, serum-free and chemically defined media (CDM) have been developed. However, the effectiveness of serum-free media is limited as many cell lines still require serum in order to grow, and many serum-free media formulations can only support the growth of narrowly-defined types of cells. [3]

Production

FBS is a by-product of the meat industry. FBS, as with the vast majority of animal serum used in cell culture, is produced from blood collected at commercial slaughterhouses from cattle that also supply meat intended for human consumption. [4]

The first stage of the production process for FBS is the harvesting of blood from the bovine fetus after the fetus is removed from the slaughtered cow. The fetus dies from the lack of oxygen by remaining in the protective environment of the uterus for a minimum of 15–20 minutes after the cow is dead. [5] The blood is collected aseptically into a sterile container or blood bag and then allowed to clot. The normal method of collection is cardiac puncture. This minimizes the danger of serum contamination with micro-organisms from the fetus itself, and the environment, while maximizing the volume of blood collected. The collected blood is then transferred to a sterile container or blood bag, where it is left to clot naturally before further processing. The clotting process separates the cellular components from the serum, producing a clear, straw-colored liquid. [1] The serum is frozen prior to further processing that is necessary to make it suitable for cell culture. [6]

The second stage of processing involves filtration, typically using a filtration chain with the final filtration being three sterile 0.1 micron membrane filters. The aseptically processed FBS is subjected to stringent quality control testing and is supplied with a detailed Certificate of Analysis. The certificate gives full test results and information concerning the origin of the serum. Certificates of Analysis vary between commercial suppliers, but each usually includes the following details: filtration statement, country of blood collection, country of manufacture, cell growth performance testing, microbial sterility testing, as well as screening for mycoplasma and virus, endotoxin, hemoglobin, IgG gamma glutamyl transferase [7] and total protein assays. FBS may also be tested for country of collection. [8]

Ethics

Ethical questions have been raised regarding the blood collection process due to the potential suffering caused to the fetus. There has been discussion with concerns regarding fetal suffering, humane treatment, and transparency in the collection process. [1] The International Serum Industry Association (ISIA) has published literature [9] [10] providing detail on the extensive regulation and processes employed to ensure that serum is collected in an ethical manner. Although the act of slaughter of the dam and the time which passes in the slaughter process prior to harvesting will induce unconsciousness or death of the fetus prior to serum harvesting, it has been postulated that exposure of live unborn calves to oxygen could cause them to gain awareness before being killed, resulting in active debate about the ethics of harvesting serum. [11] [12] While the Industry Association accepts that certain organizations have concerns, they maintain that all collections of serum take place under veterinary supervision in registered slaughterhouses controlled by the competent authority in the country of collection.

Serum use

Frozen fetal bovine serum Fetal bovine serum.jpg
Frozen fetal bovine serum

Fetal bovine serum is commercially available from many manufacturers, and because cells grown in vitro are highly sensitive, customers usually test specific batches to check for suitability for their specific cell type. When changing from batch to batch it is usual to adapt the cells to the new batch of material, for example, by mixing 50% of the old serum with 50% of the new serum and allowing the cells to acclimatize to the new material.

Serum is stored frozen to preserve the stability of components such as growth factors. When serum is thawed, some precipitation may be seen. This is a normal phenomenon, and it does not compromise the quality of serum in any way. The precipitate may be removed by transferring the serum to sterile tubes and centrifuging for 5 minutes at 400 × g. To limit the amount of precipitation, it is recommended that the serum is thawed in a refrigerator at 2-8˚C. The serum should be regularly stirred during this process. Repeated freeze/thaw cycles should be avoided, and it is advisable to dispense the serum into single use aliquots before freezing. [13]

Source history

Serum produced for use in the biotechnology industry and research sectors is highly regulated. The collection and movement of all animal derived products globally is strictly controlled. Veterinary control of animal derived products largely follows the regulations set by the EU (DG SANCO) and the US (USDA). The current regulation governing the importation of animal by-products into the EU is covered by Regulation (EU) 1069/2009 and the implementation document Regulation (EU) 142/2011.

FBS is a product collected worldwide with the main collections being centered in the United States, Australia, New Zealand, Canada, Central America, South America, and Europe.

Global sales

Sales of FBS in 2008 were estimated to be 700,000 liters globally.[ citation needed ] A 2012 source estimates that about 600,000 liters are made annually, one third of which is suitable for pharmaceutical use under Good Manufacturing Practice. 1 to 3 fetuses are required to produce one liter of serum. [14] The demand for FBS remains high due to its critical role in biopharmaceutical research and vaccine production, despite growing interest in serum-free alternatives. Market fluctuations, regulatory policies, and ethical concerns continue to shape production and pricing trends worldwide. [15]

Replacements

Proposed replacements for FBS include:

See also

References

  1. 1 2 3 Van der Valk, J.; Brunner, D.; De Smet, K.; Fex Svenningsen, Å.; Honegger, P.; Knudsen, L. E; Gstraunthaler, G. (2010). "The humane collection of fetal bovine serum and possibilities for serum-free cell culture". Toxicology in Vitro. Retrieved 13 March 2025.
  2. Dirks WG (2021). "Ethical Challenges Using Human Tumor Cell Lines in Cancer Research". Ethical Challenges in Cancer Diagnosis and Therapy. Recent Results in Cancer Research. Vol. 218. pp. 39–46. doi:10.1007/978-3-030-63749-1_4. ISBN   978-3-030-63748-4. PMID   34019161. S2CID   235072805.
  3. Yao T, Asayama Y (April 2017). "Animal-cell culture media: History, characteristics, and current issues". Reproductive Medicine and Biology. 16 (2): 99–117. doi:10.1002/rmb2.12024. PMC   5661806 . PMID   29259457.
  4. "Terrestrial Animal Health Code" . Retrieved 2021-12-10.
  5. Hawkes, Percy (January 2019). "Fetal Bovine Serum and the Slaughter of Pregnant Cows: Animal Welfare and Ethics". BioProcessing Journal. 18: 4. doi:10.12665/J18OA.Hawkes . Retrieved 8 January 2024.
  6. "Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications". Food and Drug Administration . Retrieved 2021-12-10.
  7. Cheever M, Master A, Versteegen R (22 December 2017). "A Method for Differentiating Fetal Bovine Serum from Newborn Calf Serum". BioProcessing Journal. 16. doi:10.12665/J16OA.CHEEVER.
  8. Versteegen R, Shatova O, Lind S, Linterman K (15 May 2019). "Testing for Geographic Origin of Fetal Bovine Serum". BioProcessing Journal. 18. doi:10.12665/J18OA.Versteegen. S2CID   182766915.
  9. Versteegen RJ, Murray J, Doelger S (2021). "Animal welfare and ethics in the collection of fetal blood for the production of fetal bovine serum". Altex. 38 (2): 319–323. doi: 10.14573/altex.2101271 . PMID   33871036. S2CID   233298304.
  10. van der Valk J, Brunner D, De Smet K, Fex Svenningsen A, Honegger P, Knudsen LE, et al. (June 2010). "Optimization of chemically defined cell culture media--replacing fetal bovine serum in mammalian in vitro methods". Toxicology in Vitro. 24 (4): 1053–1063. Bibcode:2010ToxVi..24.1053V. doi:10.1016/j.tiv.2010.03.016. hdl: 1874/191398 . PMID   20362047. S2CID   205410680.
  11. Mellor DJ, Gregory NG (February 2003). "Responsiveness, behavioural arousal and awareness in fetal and newborn lambs: experimental, practical and therapeutic implications". New Zealand Veterinary Journal. 51 (1): 2–13. doi:10.1080/00480169.2003.36323. PMID   16032283. S2CID   32259690.
  12. Jochems CE, van der Valk JB, Stafleu FR, Baumans V (March 2002). "The use of fetal bovine serum: ethical or scientific problem?". Alternatives to Laboratory Animals. 30 (2): 219–227. doi: 10.1177/026119290203000208 . PMID   11971757. S2CID   27361021.
  13. Hillebrand JJ, Heijboer AC, Endert E (February 2003). "Effects of repeated freeze-thaw cycles on endocrine parameters in plasma and serum". Annals of Clinical Biochemistry. 54 (2): 289–292. doi:10.1080/00480169.2003.36323. PMID   16032283. S2CID   32259690.
  14. Brindley, DA; Davie, NL; Culme-Seymour, EJ; Mason, C; Smith, DW; Rowley, JA (January 2012). "Peak serum: implications of serum supply for cell therapy manufacturing". Regenerative Medicine. 7 (1): 7–13. doi:10.2217/rme.11.112. PMID   22168489.
  15. Gstraunthaler, G.; Lindl, T.; Van Der Valk, J. (2013). "A serious problem with fetal bovine serum". Alternatives to Laboratory Animals. Retrieved 13 March 2025.
  16. 1 2 3 4 Subbiahanadar Chelladurai, K; Selvan Christyraj, JD; Rajagopalan, K; Yesudhason, BV; Venkatachalam, S; Mohan, M; Chellathurai Vasantha, N; Selvan Christyraj, JRS (August 2021). "Alternative to FBS in animal cell culture - An overview and future perspective". Heliyon. 7 (8): e07686. Bibcode:2021Heliy...707686S. doi: 10.1016/j.heliyon.2021.e07686 . PMC   8349753 . PMID   34401573.